Ignacio Melero

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau et al. · The Lancet · 2017 · 4.3K citations · Full text

Medicine, Oncology, Pharmacology +13

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

Thomas Yau, Yoon‐Koo Kang, Tae‐You Kim et al. · JAMA Oncology · 2020 · 1.2K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

Bruno Sangro, Carlos Gómez-Martín, Manuel de la Mata et al. · Journal of Hepatology · 2013 · 988 citations

Medicine, Oncology, Pharmacology +15

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

Ignacio Melero, Walter W. Shuford, S A Newby et al. · Nature Medicine · 1997 · 891 citations

Life Sciences, Immunology, Oncology +14

Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

Jun Wang, Miguel F. Sanmamed, Ila Datar et al. · Cell · 2018 · 883 citations

Life Sciences, Immunology, Molecular Biology +7